Welling to Lead New Liver Cancer Program at NYU Langone

Theodore H. Welling III, MD

Theodore H. Welling III, MD

NYU Langone has announced Theodore H. Welling III, MD, will lead a new state-of-the-art liver cancer program at the medical center to advance clinical care and accelerate the translation of lab breakthroughs into superior treatments.

Previously co-director of the Multidisciplinary Liver Tumor Program at the University of Michigan Health System, Welling joins NYU Langone’s Perlmutter Cancer Center to lead a team that has already made important strides in refining clinical practices to treat primary liver cancer and hepatic metastases, according to a release from NYU Langone. He will help to recruit additional investigators and clinicians to the program.

Welling’s appointment also complements important programmatic and research efforts already underway through NYU Langone’s Transplant Institute, whose specialists will work collaboratively with the Liver Cancer Program to foster a team approach in personalized and comprehensive commitment to patient care, according to the release.

“I am extremely excited to have the opportunity to lead such an innovative clinical and translational Liver Tumor Program designed to advance therapies for hepatic malignancies,” Welling said. “The vision and leadership of NYU Langone and its Perlmutter Cancer Center has led to the creation of an excellent team of health care providers and researchers to help accomplish this mission.”

Welling earned his medical degree from the University of Michigan Medical School, where he also completed his residency in general surgery and a two-year surgical fellowship in transplant surgery. Welling joined the surgical faculty at the medical school and the University of Michigan Health System in 2007.

His published studies have appeared in leading peer-reviewed journals, includingLancet,Cancer Research, GastroenterologyandHepatology, among others. He also has authored many book chapters and review articles, and has lectured extensively both nationally and internationally.  

Welling is a member of several professional societies and has served or currently serves on many committees associated with these organizations. He also has received several awards and commendations from his peers for his commitment to clinical care, education and research.

“Like many malignancies, symptoms of liver cancer do not appear in early stages, so it tends to be diagnosed when it is more advanced and less likely to be cured,” said Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center. “Our goal is to help change the course of this disease, develop better ways to identify it early and improve patient outcomes. We are confident that under Dr. Welling’s leadership our liver cancer program can make major advances.”